

Quick Facts About PPD

- PPD is a leading global contract research organization, celebrating 25 years of advancing drug development by providing drug discovery, development and lifecycle management services. Based in Wilmington, N.C., PPD generated \$1.42 billion in revenue in 2009.
- Our common stock is traded under the symbol “PPDI” and is quoted on the Nasdaq Global Select Market.
- Founded in 1985 as a one-person consulting firm by Dr. Fred Eshelman, PPD has offices in 42 countries and more than 11,000 employees worldwide. We have the expertise and infrastructure to conduct regional and multinational clinical studies throughout North America; Europe, Middle East and Africa; Latin America and Asia Pacific.
- PPD serves a wide range of global clients and partners, including pharmaceutical, biotechnology, medical device, academic and government organizations. We work with almost all of the top 50 pharmaceutical and biotechnology companies.
- Our world-class teams, strong therapeutic expertise, leading-edge technologies, high-quality services, global infrastructure and leadership are why we are at the forefront of the drug development services market.
- We specialize in a wide range of therapeutic areas including oncology, infectious diseases, endocrine/metabolic, and cardiovascular and central nervous system, closely aligning with industry’s top research and development priorities.

Laboratory Services

We apply scientific expertise for drug discovery as well as resources for early compound assessment and development.

- BioDuro, A PPD[®] Company
- Nonclinical development
- Preclinical services
- Phase I clinic
- GLP bioanalytical, cGMP product analysis, biomarker, vaccines and biologics, and Phase I-IV global central labs

Clinical Development Services

PPD provides comprehensive product development and post-approval services for biopharmaceuticals and devices.

- Full service Phase II-IIIb clinical studies for multinational regulatory submissions
- Therapeutic and specialty expertise with dedicated project teams
- Post-approval services, including epidemiology: pharmacoepidemiology and health outcomes; risk management, REMS; safety surveillance studies, late stage studies; medical information; product safety; registries and observational studies
- Clinical data management and information solutions, including consulting and proprietary software tools to speed collection, analysis and reporting of clinical data